StockData
Aclaris Therapeutics, Inc. logo

Aclaris Therapeutics, Inc. (ACRS) stock

ACRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30146% above fair value
$3.44−0.06 (-1.71%)

Close on Nov 20, 2026Market cap $506.36MP/E –Yield –

Aclaris Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Aclaris Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$62.18M. For fiscal 2025 it was -$47.22M. The highest annual figure on record is -$8.05M in fiscal 2014.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$47.22M–
FY2024Dec 31, 2024-$20.20M–
FY2023Dec 31, 2023-$79.63M–
FY2022Dec 31, 2022-$68.17M–
FY2021Dec 31, 2021-$52.44M–
FY2020Dec 31, 2020-$39.09M–
FY2019Dec 31, 2019-$98.06M–
FY2018Dec 31, 2018-$102.17M–
FY2017Dec 31, 2017-$55.90M–
FY2016Dec 31, 2016-$34.84M–
FY2015Dec 31, 2015-$20.88M–
FY2014Dec 31, 2014-$8.05M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$19.91M–
Q1 FY2026Mar 31, 2026-$18.16M–
Q4 FY2025Dec 31, 2025-$13.16M–
Q3 FY2025Sep 30, 2025-$10.96M-149.8%
Q2 FY2025Jun 30, 2025-$10.01M–
Q1 FY2025Mar 31, 2025-$13.10M–
Q4 FY2024Dec 31, 2024-$8.94M–
Q3 FY2024Sep 30, 2024$22.00M–
Q2 FY2024Jun 30, 2024-$12.31M–
Q1 FY2024Mar 31, 2024-$20.95M–
Q4 FY2023Dec 31, 2023-$7.20M–
Q3 FY2023Sep 30, 2023-$24.64M–
Q2 FY2023Jun 30, 2023-$20.89M–
Q1 FY2023Mar 31, 2023-$26.91M–
Q4 FY2022Dec 31, 2022-$19.22M–
Q3 FY2022Sep 30, 2022-$7.97M–
Q2 FY2022Jun 30, 2022-$19.85M–
Q1 FY2022Mar 31, 2022-$21.13M–
Q4 FY2021Dec 31, 2021-$17.28M–
Q3 FY2021Sep 30, 2021-$10.66M–
Q4 FY2020Dec 31, 2020-$8.87M–
Q3 FY2020Sep 30, 2020-$12.45M–
Q2 FY2020Jun 30, 2020-$10.84M–
Q1 FY2020Mar 31, 2020-$6.93M–
Q4 FY2019Dec 31, 2019-$20.66M–
Q3 FY2019Sep 30, 2019-$24.18M–
Q2 FY2019Jun 30, 2019-$21.62M–
Q1 FY2019Mar 31, 2019-$31.60M–
Q4 FY2018Dec 31, 2018-$27.39M–
Q3 FY2018Sep 30, 2018-$30.42M–
Q2 FY2018Jun 30, 2018-$22.19M–
Q1 FY2018Mar 31, 2018-$22.17M–
Q4 FY2017Dec 31, 2017-$18.79M–
Q3 FY2017Sep 30, 2017-$13.98M–
Q2 FY2017Jun 30, 2017-$10.27M–
Q1 FY2017Mar 31, 2017-$12.85M–
Q4 FY2016Dec 31, 2016-$8.13M–
Q3 FY2016Sep 30, 2016-$9.97M–

More Aclaris Therapeutics figures

See a number that looks wrong?